News Archive

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM listed Yourgene Health plc (“Yourgene”), the international molecular diagnostics group which develops and commercialises genetic products and services. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

Yourgene’s first commercialised product is the CE marked IONA® test, a non-invasive prenatal test (NIPT) for Down’s syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market. The IONA® test is performed by analysing cell-free placenta-fetal DNA from a maternal blood sample, reducing the need for invasive tests and the associated stress and anxiety.

In April 2019 Yourgene Health acquired Elucigene Diagnostics, a leading molecular diagnostics manufacturer and developer focused on reproductive health and oncology. Elucigene brings a complementary product portfolio to Yourgene, including cystic fibrosis screening, and the opportunity to expand into further oncological (BRCA 1/BRCA 2, colon, lung) and fertility (male, non-invasive paternity, pre-eclampsia) testing.

For more information visit the Company’s website: www.yourgene-health.com

For further information please contact:

About Walbrook PR: www.walbrookpr.com

Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.

Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.

Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.